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Analysis of 4,405 variants in 89,050 European subjects from 41 case-control studies identified three independent association signals for
estrogen-receptor-positive tumors at 11q13. The strongest signal maps to a transcriptional enhancer element in which the G allele of the
best candidate causative variant rs554219 increases risk of breast cancer, reduces both binding of ELK4 transcription factor and luciferase
activity in reporter assays, and may be associated with low cyclin D1 protein levels in tumors. Another candidate variant, rs78540526,
lies in the same enhancer element. Risk association signal 2, rs75915166, creates a GATA3 binding site within a silencer element. Chro-
matin conformation studies demonstrate that these enhancer and silencer elements interact with each other and with their likely target
gene, CCND1.Introduction
One of the strongest breast cancer associations identified to
date via genome-wide association studies (GWASs) is with
SNP rs614367 at the 11q13 locus (OR ¼ 1.21; 95% CI
1.17–1.24; p ¼ 1039). This association is restricted to
estrogen-receptor-positive (ERþ) tumors.1,2 SNP rs614367
maps to a 350 kb intergenic region, with MYEOV13
(MIM 605625) being the nearest centromeric gene and
CCND1 (MIM 168461), ORAOV1 (MIM 607224), and
several genes of the fibroblast growth factor family (FGF3
[MIM 164950], FGF4 [MIM 164980], and FGF19 [MIM
603891]) all lying telomeric, any of which are plausible
candidate breast-cancer-susceptibility genes. Although
this SNP lies in a gene desert, chromatin modifications
suggest that this region contains multiple regulatory
elements. Of note, this interval also contains risk SNPs for
renal (MIM 144700)3 and prostate (MIM 176807) cancer.4–
7 Here we report the fine-scale mapping of this locus via
731 SNPs directly genotyped on the custom-designed
iCOGS (international Collaborative Oncology Gene-
environment Study) Illumina chip together with multiple
analyses aimed at exploring the functions of the top inde-
pendent signals of association with breast cancer.Material and Methods
Genetic Mapping
Tagging Strategy for Fine-Scale Mapping
In March 2010, when the iCOGS chip was designed, the 1000
Genomes Project (2012) had cataloged 10,358 variants at the118Centre for Molecular Epidemiology, National University of Singapore, S
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The Am11q13 locus (positions 68,935,424–69,666,272; NCBI build
37 assembly), of which 2,259 had a minor allele frequency
(MAF) >0.02. From these, we selected all SNPs having r2 > 0.10
with the originally detected SNP, rs614367, plus a set of SNPs
designed to tag all uncorrelated SNPs with r2 > 0.8. After comple-
tion of iCOGs genotyping, this initial set was supplemented with
a further four SNPs, selected from the October 2010 (Build 37)
release of the 1000 Genomes Project, to improve coverage. These
were genotyped in two large BCAC (CCHS and SEARCH) studies
comprising 12,273 cases and controls, using a Fluidigm array
according to manufacturer’s instructions. Using the above data,
results for all the additional known common variants on the
January 2012 release of the 1000 Genomes Project were imputed
with IMPUTE version 2.0. Genotypes at 3,674 SNPs were reliably
imputed (imputation r2 score > 0.3) and were analyzed together
with the 731 genotyped SNPs—giving a total of 4,405 SNPs within
the ~730 kb LD region.
iCOGS Genotyping
Samples were drawn from 50 studies participating in the BCAC: 41
from populations of predominantly European ancestry and 9 of
Asian ancestry (unpublished data). Studies were required to
provide ~2% of samples in duplicate. All BCAC studies had local
human ethical approvals.8
Statistical Analysis
For each SNP, we estimated a per-allele log-odds ratio (OR) and
standard error by logistic regression, including study and prin-
cipal components as covariates. Genotype data for all subjects
of European ancestry in the study were imputed with the
IMPUTE V2.0 software with one phased (January 2012 version
of 1000 Genomes project data) and one unphased (CCHS and
SEARCH data that were genotyped on the additional four
SNPs) reference panel. Association analyses were based on
imputed SNPs with estimated MAF > 0 and imputation accuracy
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Conditional analyses were performed to identify SNPs indepen-
dently associated with the phenotype in question. To identify
the most parsimonious model, all SNPs with a p value <0.0001
and MAF >0.02 in the single SNP analysis were included in
forward selection regression analyses with penalty k ¼ 10 in the
step function in R. Haplotype-specific ORs were estimated by
in-house methods based on the tagSNPs program9 and haplo-
stats.10 Study and principal components were included as covari-
ates. The contribution of 11q13 variants to the familial risk of
breast cancer was estimated with the formula log(lL)/log(l0).
Here lL is the familial relative risk to daughters of individuals
with breast cancer explained by the locus under an additive
model, given by
lL ¼
PK
k¼1
pkj
2
k
PK
k¼1
pkjk
2;
where K is the number of alleles or haplotypes, pK is the frequency
of the kth allele (haplotype), and cK is the per-allele (per-haplo-
type) relative risk. l0 is the overall familial relative risk to degree
relatives of individuals with breast cancer, assumed to be 2. For
ER-positive breast cancer, the same overall familial relative risk
(l0 ¼ 2) was assumed. p values for evaluation of differences in cy-
clin D1 protein levels by SNP genotypewere calculated with c2 test
or Fisher’s exact test by SPSS v18.0.2 (SPSS, Inc.).
CCND1 Protein and Gene Expression
Tissue microarrays (TMAs) were previously constructed on 1,348
invasive breast tumors from the HEBCS study and processed as
described,11 including four cores (diameter 0.6 mm) of the most
representative area from each formalin-fixed and paraffin-
embedded breast cancer specimen. For cyclin D1 protein levels,
TMA slides were stained with cyclin D1 (Novocastra) antibodies
(diluted 1:20). Cyclin D1-positive cells were counted in one
high-power field (objective 403) in each of the four cores on
TMA. Only unequivocal positive nuclear staining was accepted
as a positive reaction. A minimum of 200 breast cancer cells was
counted in each tumor. The result was the percentage of all posi-
tive cells from the entire number of breast cancer cells counted
from the four biopsies. Tumors with expression levels below
1% were considered as negative and above 1% as positive
(Figure S1). In total, 644 individuals with breast cancer had both
TMA information and genotypic data (genotyped in iCOGS),
and 512 of the breast tumors were ER positive. The correlation
of SNP rs554219 and cyclin D1 protein levels was examined in
the presence of SNP rs75915166 common homozygotes.
To perform eQTL analyses with data from breast cancer cases in
The Cancer Genome Atlas Project, we downloaded data from 382
TCGA breast cancer cases from the TCGA data portal. We obtained
germline SNP data by using the birdseed genotype calls from the
Level 2 Affymetrix 6.0 arrays on peripheral blood. We obtained
the normalized log2 tumor gene expression profiling data from
the level 2 Agilent microarray data. Germline SNPs were imputed
to the 1000 Genomes data set by PLINK. We assessed the associa-
tion of the germline risk alleles with tumor CCND1 expression in
the 301 ERþ breast cancers.
Cell Lines
Breast cancer cell lines MDAMB415, CAL51, MCF7, MDAMB231,
PMC42, and HCC1954 were grown in DMEM medium with 10%492 The American Journal of Human Genetics 92, 489–503, April 4, 2FCS and antibiotics under standard conditions, while T47D was
grown in RPMI medium with the same supplements. Where rele-
vant, cell lines were genotyped with fluorescent 50exonulease
assay (TaqMan) and the ABI prism 7900 Sequence Detection
System (PE Biosystems) in a 384-well format.
Chromatin Interaction Analysis by Paired-End Tag
Sequencing Analysis
PETCluster data files representing two ChIA-PET libraries
(IHM001F and IH015F) prepared with ER antibodies in MCF7
cells were downloaded from the ChIA-PET Browser. Analysis of
interactions within the putative regulatory element 1 (PRE1;
NCBI build 36 chr11: 69,036,648–69,042,291) was conducted in
R/Bioconductor. Closest neighbor genes were identified with the
Bioconductor package ChiPpeakAnno.
Chromatin Conformation Capture
Chromatin conformation capture (3C) libraries were generated
with HindIII and DpnII as described previously.12 3C interactions
were quantitated by real-time PCR with primers designed within
the restriction fragments of interest (Table S4). qPCR was per-
formed on a RotorGene 6000 using MyTaq HS DNA polymerase
(Bioline) with the addition of 5 mM of Syto9, annealing tempera-
ture of 66C, and extension of 30 s. HindIII 3C analysis of
MCF7 cells was performed in two independent experiments.
DpnII 3C analysis of MCF7 cells was performed in three indepen-
dent experiments, and T47D, MDAMB231, and CAL51 analysis
was performed in two independent experiments. Each experiment
was quantified in triplicate. Two BAC clones (RP11-156B3
and RP11-378K8) covering the 11q13/CCND1 region were used
to create an artificial library of ligation products in order to
normalize for PCR efficiency. Data were normalized to the signal
from the BAC clone library and, between cell lines, by reference
to a region within GAPDH. All qPCR products were electrophor-
esed on 2% agarose gels, gel purified, and sequenced to verify
the 3C product.
Plasmid Construction and Luciferase Assays
A CCND1 promoter-driven luciferase reporter construct was gener-
ated by inserting a 2,746 bp fragment containing the CCND1
promoter into the KpnI and HindIII sites of pGL3-basic. To assist
cloning, AgeI, NheI, and SbfI sites were inserted into the BamHI
and SalI sites downstream of luciferase. A 3,340 bp fragment con-
taining PRE1 was inserted into the AgeI and SbfI sites or a 955 bp
fragment containing the putative regulatory element 2 (PRE2) was
inserted into the BamHI and SalI sites downstream of luciferase.
Individual SNPs were incorporated into PRE1 and PRE2 via overlap
extension PCR. PRE2 was incorporated into PRE1 containing
constructs by inserting PRE2 into NheI and SalI sites downstream
of PRE1. All constructs were sequenced to confirm variant incorpo-
ration (AGRF, Australia). Primers used to generate all constructs are
listed in Table S4.
MCF7, T47D, or CAL51 cells were transfected with equimolar
amounts of luciferase reporter plasmids and 50 ng of pRLTK
with Lipofectamine 2000. The total amount of transfected
DNA was kept constant per experiment by adding carrier
plasmid (pUC19). Luciferase activity was measured 24 hr post-
transfection by the Dual-Glo Luciferase Assay System on a Beck-
man-Coulter DTX-880 plate reader. To correct for any differ-
ences in transfection efficiency or cell lysate preparation,
Firefly luciferase activity was normalized to Renilla luciferase.013
The activity of each test construct was calculated relative to
CCND1 promoter construct, the activity of which was arbi-
trarily defined as 1. For knockdown experiments, MCF7 cells
were cotransfected with the relevant luciferase reporter plasmids
and either 100 nM of Dharmacon SMARTpool siRNA or shRNA
plasmids with Lipofectamine 2000 (Invitrogen). 48 hr after
transfection, the luciferase activity was performed as described
above.siRNA Knockdown
ON-TARGETplus SMARTpool siRNAs for GABPA (MIM 600609;
L-011662-00) and GATA3 (MIM 131320; L-003781-00) and
nontargeting siRNA (D-001810-10-20) were purchased from
Dharmacon (Thermo Scientific). Two ELK4 (MIM 600246) small
hairpin shRNA constructs corresponding to two independent
shRNA sequences have been described previously.13Quantitative PCR
Total RNA was extracted with Trizol (Invitrogen) and reverse tran-
scribed with random hexamers and SuperScriptIII (Invitrogen)
according to manufacturers’ instructions. qPCR was performed
on a RotorGene 6000 (Corbett Research) with TaqMan Gene
Expression assays (Hs00360812_m1 for ELK4, Hs00231122_m1
for GATA3, and Hs01022023_m1 for GABPA) and TaqMan
Universal PCR master mix. All reactions were normalized against
b-glucuronidase (MIM 611499; Cat# 4326320E).Electrophoretic Mobility Shift Assay
Small-scale nuclear extracts and bandshifts were carried out as
previously described14 and oligonucleotide sequences used in
the assays are listed in Table S4. Antisera were obtained from Santa
Cruz Biotech: rabbit polyclonal antisera were used against USF1
(sc229x), USF2 (sc862x), SP1 (sc14027x), GABPA (sc228x), and
ELK4 (sc13030x). GATA3 (sc268x) was detected with mouse
monoclonal antibodies. Competitor oligonucleotides were used
at 10-, 30-, and 100-fold molar excess.Chromatin Immunoprecipitation
Chromatin immunoprecipitation (ChIP) experiments were
carried out as previously described.15 In brief, cells were cross-
linked in 1% formaldehyde for 10 min at room temperature
before harvesting and washing in PBS, 13 protease inhibitors
(PI; Roche). Cells were lysed and washed to remove the cyto-
plasm and the nuclei resuspended in LB3 (10 mM Tris-HCl [pH
8], 100 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 0.1% sodium-de-
oxycholate, 0.5 N-laurylsarcosine, 13 PI) and sonicated for 15
cycles (30 s on, 30 s off, 4C, high setting) on a Diagenode Bio-
rupter. Lysates were cleared at 14,000 3 g for 10 min and incu-
bated with 10 mg of antibody and 10 ml of Protein-G beads (Dy-
nal) for 12 to 18 hr at 4C (antibodies as for EMSA). Beads were
washed in RIPA buffer and DNA isolated by standard methods (-
QIAGEN). DNA was quantitated with Quant-IT and equal
amounts of precipitate and input used in RT-PCR reaction with
primers given in Table S4. Allele-specific PCR was carried out
with TaqMan Genotyping Assays (predesigned assays, ABI). All
values obtained are normalized to input and enrichment is given
relative to the negative CCND1 control.16 Each ChIP has yielded
similar results in at least two independent experiments. The
error bars denote the standard deviation in three technical
repeats.The AmIn Silico Analysis of GATA3 Binding
To examine the potential of GATA3 to bind rs75915166, we calcu-
lated the enrichment of the 6 bp motif overlapping the core of the
position weight matrix (PWM) of the GATA3 motif around this
SNP in the 75 bp either side of all GATA3 ChIP-seq peaks,17
compared to random genomic sequences of the same length.
Furthermore, to examine the differential enrichment underneath
GATA peaks for the motif containing the A allele over the T allele,
the relative enrichment between proportions of peaks containing
these motifs was compared to relative enrichments observed
within 100,000 sets of random intergenic sequences. Enrichment
of the motif containing the A allele compared to T under GATA
peaks was compared to the bootstrapped distribution of relative
enrichments within random genomic regions yielding a p value
of 0.0147.Results
Case-Control Studies
The original GWAS-associated SNP, rs614367, tags a linkage
disequilibrium (LD) block of 683 kb spanning chromo-
some 11 positions 68,935,424–69,666,272 (NCBI build
37 assembly), as defined by the furthest telomeric and
centromeric SNPs displaying detectable correlation (r2 >
0.10) with rs614367. With data from the 1000 Genomes
Project, we cataloged 10,358 variants in the region and
selected a subset of these to cover the entire region (see
Material and Methods). Of these, 731 SNPs were success-
fully designed and genotyped on the iCOGS chip in 41
case-control studies from populations of European
ancestry (89,050 subjects) and 12,893 subjects from 9
case-control studies of Asian ancestry within BCAC
(Supplemental Data). Genotypes of all other known
variants in the locus were imputed in the European
studies by using known genotypes in combination with
data from the 1000 Genomes Project. 3,674 SNPs were
reliably imputed (imputation r2 score > 0.3) and were
considered for further analysis together with the 731
genotyped SNPs.
Based on data from all European studies, 204 genotyped
or imputed SNPs were convincingly associated with overall
risk of breast cancer (p values 105 to 1064, Table S1).
Stratification by tumor ER status confirmed that all associ-
ations were with ERþ disease with no significant evidence
for any SNPs associated with ER tumors (Table S1).
Thus, all further analyses were confined to risks of ERþ
disease. A Manhattan plot of all considered SNPs at
this locus (Figure 1A) demonstrates a complex pattern of
association.Stepwise Logistic Regression Reveals Multiple
Independent Signals
To dissect this pattern of associations, all genotyped
SNPs displaying evidence for association with ERþ disease
(87 SNPs, p < 104) were included in forward stepwise
regressionmodels. Themost parsimoniousmodel included
three independent SNPs significant at p < 104 (Table 1,erican Journal of Human Genetics 92, 489–503, April 4, 2013 493
Figure 1. Genetic Mapping and Epige-
netic Landscape at the 11q13 Locus
(A) Manhattan plot of the 11q13 suscepti-
bility locus for breast cancer. Genotyped
and imputed SNPs are plotted based on
their chromosomal position on the x axis
and their overall p values (log10 values)
from the European BCAC studies on the
y axis. The six genes present in the region
are indicated in black.
(B) Epigenetic and transcriptional land-
scape at the 11q13 risk locus for breast
cancer in humanmammary epithelial cells
(HMECs). Green and red histograms
denote ChIP-seq data from HMECs
(ENCODE) and MCF7 cells stimulated
with estrogen (GEO #GSM594606); blue
denotes a heat map of ERa ChIA-PET data
from MCF7s treated with estradiol.16 Red
bars denote cohesin (ArrayExpress; #E-
TABM-828), ERa (GEO #GSM365926),
and FoxA118 ChIP-seq data from MCF7
cells. Abbreviations are as follows: PRE1,
putative regulatory element 1 that con-
tains SNPs 1–4; PRE2, putative regulatory
element 2 that contains SNP5. Below
depicts the pattern of linkage disequilib-
riumwith data from the BCACpopulation,
where white represents r2 ¼ 0 and black
r2 ¼ 1. Red stars denote the positions of
SNPs 1–4 in the linkage block.Figure 1A). These were (1) SNP rs554219 (OR per minor
allele ¼ 1.33; 95% CI 1.28–1.37; p value 1066; conditional
p value 3.7 3 1026); (2) SNP rs75915166 (OR per minor
allele¼ 1.38; 95%CI 1.32–1.44; p value 2.73 1046; condi-
tional p value 2.73 108); and (3) rs494406 (OR per minor
allele ¼ 1.07; 95% CI 1.05–1.1.11; p value 3.7 3 109;
conditional p value 2.6 3 106) (Figure 1A).
Variants for subsequent functional analysis were
selected, on the basis of the above analysis of genotyped
SNPs, according to the following criteria: assuming a single
causative variant for each of the independent signals, we
calculated the likelihood ratio of each SNP relative to
best independent signal with which it was correlated.
SNPs with a likelihood of <1:100 compared with the
most significant SNP for each signal were excluded from
consideration as being potentially causative. For signal 1,
four SNPs clustered in a 20 kb region (position:494 The American Journal of Human Genetics 92, 489–503, April 4, 201369,320,000–69,340,000 build 37) re-
mained after this exclusion process:
rs661204 (SNP1), rs78540526
(SNP2), rs554219 (SNP3), and
rs657686 (SNP4). For signal 2, only
SNP rs75915166 (SNP5) remains; all
other SNPs correlated with this one
had much less significant effects. Of
note rs75915166 is partially corre-
lated with the signal 1 SNPs (r2 with
rs554219 ¼ 0.61) but conditional
analysis indicates it is clearly inde-pendent (p value 5 3 108 after conditioning on
rs554219). For signal 3, four SNPs (rs494406, rs585568,
rs593679, rs679162) remain as potentially causal, but
these are associated with much smaller effect sizes (Table
1). Further investigations were thus focused on the five
SNPs (SNP1–SNP5; listed above) for which there was stron-
gest evidence for likely causation.
When the stepwise regression was repeated, after
imputation of all SNPs in the locus to the January 2012
release of the 1000 Genomes data, the most parsimonious
model included (1) SNP rs78540526 (SNP2; conditional p
value 4 3 1010); (2) SNP rs554219 (SNP3; conditional p
value 9 3 108); and (3) a newly discovered variant at
chromosome 11: SNP rs12575120 (conditional p value
3 3 106). No overall evidence of heterogeneity was
observed for the genotyped SNPs, which we selected for
functional analysis, among the European or Asian studies
Table 1. Association of the Three Independent SNPs Is Strictly Confined to ERþ Breast Cancer
Signal SNPs
Chromosome
Positiona MAFb OR ERþ 95% CI p Trend OR ER 95% CI p Trend
p Value in Logistic
Regression
Signal 1 rs554219 69331642 0.123 1.33 (1.28–1.37) 5.64 3 1066 1.02 (0.97–1.08) 0.47 3.7 3 1026
rs657686 69332670 0.122 1.33 (1.29–1.37) 4.07 3 1066 1.02 (0.97–1.08) 0.44
Signal 2 rs75915166c 69379161 0.059 1.38 (1.32–1.44) 2.70 3 1046 1.06 (0.99–1.15) 0.11 2.7 3 108
Signal 3 rs494406 69344241 0.255 1.07 (1.05–1.11) 3.73 3 109 1.02 (0.98–1.07) 0.34 2.6 3 106
rs585568 69345336 0.255 1.07 (1.05–1.11) 4.96 3 109 1.02 (0.98–1.06) 0.35
rs679162 69344477 0.255 1.07 (1.05–1.11) 5.15 3 109 1.02 (0.98–1.06) 0.36
rs593679 69342650 0.255 1.07 (1.05–1.11) 3.76 3 109 1.02 (0.98–1.06) 0.36
Previously reported
GWAS variant
rs614367 69328764 0.161 1.26 (1.22–1.30) 1.28 3 1051 1.02 (0.97–1.08) 0.40 –
These three SNPs (rs554219, rs75915166, and rs494406) remain in a forward stepwise logistic regression analysis that included all associated SNPs with ERþ
(p < 0.0001) and MAF > 0.02.
aBuild 37.
bMAF in controls.
cAlso named pos69088342 in build 36.(p > 0.08) (Figure S2). The minor allele frequencies
(MAFs) of these SNPs are much rarer in Asian populations
than in Europeans (rs554219 and rs657686, MAF ¼ 0.017;
rs75915166 and rs661204, MAF < 0.01) although
SNP rs78540526 appeared to be monomorphic in
Asians (Table S3). Despite this, the SNPs with detectable
minor alleles in Asians have risk estimates for ERþ tumors
consistent with those in Europeans (rs554219 [SNP3]:
OR ¼ 1.64; 95% CI 1.27–2.11; p value ¼ 1.3 3 104;
rs657686 [SNP4]: OR ¼ 1.61; 95% CI 1.25–2.07; p value ¼
2.2 3 104; rs75915166 [SNP5], OR ¼ 1.42, p value ¼
3.6 3 102). These significant associations, despite the
rarity of the minor alleles in Asian populations, provide
further support that these SNPsmay have directly causative
effects.
Three Distinct Haplotypes Confer Increased Risks
with Different Magnitudes
We conducted haplotype analysis with the five SNPs,
selected above, which define four common haplotypes
(Table 2). Haplotype H1, carrying the risk alleles of SNPs
1, 3, and 4, is associated with a significant increase in
ER-positive breast cancer risk over the commonest haplo-
type (H0) (OR ¼ 1.16, 95% CI 1.12–1.21, p value ¼ 1.6 3
108), and a second, rarer haplotype (H2) carryingTable 2. Haplotype Analysis across the BCAC Studies
Haplotypes
rs661204
(SNP1)
rs78540526
(SNP2)
rs554219
(SNP3)
rs657686
(SNP4)
1 1 0 1 1
2 1 1 1 1
3 1 1 1 1
All others rare
Each haplotype was compared to the ancestral haplotype carrying the common
correlated with each other and hence always inherited together.
The Amrisk alleles of SNPs 1, 2, 3, and 4 is associated with a signif-
icantly greater risk (OR ¼ 1.39, 95% CI 1.30–1.50,
p value ¼ 1.25 3 1020). A third haplotype, carrying all
five risk alleles, is associated with the highest risk estimate
(OR ¼ 1.44, 95% CI 1.38–1.51, p value ¼ 1.22 3 1055)
although this was not significantly higher than that
of H2.
TheMinor G Allele of SNP rs554219May Be Associated
with Reduced Cyclin D1 Protein Levels
To explore the target gene of the functional SNPs, we
looked for associations of SNPs 1–5 with gene expression
in human tissue. We observed no evidence for association
of any of these SNPs (1) with the local genes (MYEOV1,
CCND1, ORAOV1, FGF3, FGF4, and FGF19) in RNA from
40 normal breast tissue samples or (2) with CCND1 expres-
sion in 300 ERþ tumors from the TCGA project—but our
power to detect such associations in these samples was
low. In a set of 448 ERþ breast tumors from the Helsinki
Breast Cancer Study (HEBCS), signal 1 SNP rs554219
(SNP3) showed borderline evidence for association with
differences in cyclin D1 protein levels (determined by
immunohistochemistry) in a recessive model (p ¼ 0.037)
but no linear trend was visible (p ¼ 0.69, Table 3). Homo-
zygotes for the risk G allele associated with reduced cyclinrs75915166
(SNP5)
Haplotype
Frequency OR p Value
0 0.048 1.16 (1.12–1.21) 1.6 3 108
0 0.025 1.39 (1.30–1.50) 1.25 3 1020
1 0.062 1.44 (1.38–1.51) 1.22 3 1055
0.005 0.99 (0.83–1.18) 0.90
alleles of all five SNPs. SNPs rs661204, rs554219, and rs657686 are perfectly
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Table 3. Association of SNP3 rs554219 with Cyclin D1 Protein
Levels
SNP rs554219
Genotype
Cyclin D1 Protein Levels
Total
(n ¼ 448)
Negative
(n ¼ 52)
Positive
(n ¼ 396)
C/C 320 (71.4) 38 (73.1) 282 (71.2)
C/G 121 (27.0) 11 (21.2) 110 (27.8)
G/G 7 (1.6) 3 (5.8) 4 (1.0)
Protein levels (binary: negative versus positive) detected by immunohisto-
chemistry in 448 ERþ tumors from cases in the HEBCS. All included cases
were homozygous for the common allele of SNP rs75915166 (SNP5). p values
were calculated as 0.024 by heterogeneity test, 0.69 by chi-square test for
trend, and 0.037 by chi-square test for recessive model.D1 staining. To avoid possible interference of the second
independent risk variant, this analysis was carried out
only in samples homozygous for the common allele of
SNP rs75915166 (SNP5). After adjustment for rs554219,
SNP5 showed no significant correlation with cyclin D1
protein levels.
The Strongest Candidate Causal SNPs Map to Two
Putative Regulatory Elements that Distally Regulate
the CCND1 Promoter
Regulatory elements such as transcriptional enhancers
and silencers can be identified by transcription factor
(TF) occupancy and distinct chromatin marks such as
mono- and dimethylation of histone 3 lysine 4 (H3K4Me1
and H3K4Me2), which mark active promoters and
enhancers.18,19 We used available ChIP-seq data from
MCF7 cells for H3K4Me1, H3K4Me2, and selected TFs to
determine whether SNPs 1–5 fall within putative transcrip-
tional regulatory elements. Signal 1 SNPs (1–4) cluster
within a 1.7 kb LD block that falls in a putative regulatory
element (PRE) (PRE1; Figure 1B) flanked by H3K4Me1 and
H3K4Me2 marks, and signal 2 SNP5 (rs75915166) lies in
a second PRE (PRE2; Figure 1B). Notably, PRE1 binds ER
alpha (ERa), which is consistentwith the associations being
confined to ERþ tumors.2
According to ChIA-PET (chromatin-interaction anal-
ysis with paired-end tag sequencing) data generated by
Fullwood et al.,20 PRE1 is a hotspot for ER-bound chro-
matin interactions (Figure 1A), suggesting that PRE1
regulates distal genes by participating in long-range
chromatin interactions. Consistent with this, PRE1
also binds cohesin, a DNA binding protein shown to
be important in tethering long-range chromatin interac-
tions and FOXA1, a pioneer factor that initiates ERa-
chromatin binding21,22 (Figure 1B). Mining of the ERa
ChIA-PET data identified several genomic regions
participating in long-range chromatin interactions with
PRE1 in independent biological replicates (Table S3).
The CCND1 promoter, located approximately 125 kb
downstream, was the only gene promoter that repro-
ducibly interacts with PRE1, suggesting that PRE1 may
be involved in regulating CCND1 expression. Notably,496 The American Journal of Human Genetics 92, 489–503, April 4, 2the ChIA-PET data shows that PRE1 also interacts
frequently with the terminator region of CCND1, which
contains a previously reported enhancer (enh2) of
CCND1.16
Via chromosome conformation capture (3C), we con-
firmed that PRE1 frequently interacts with the CCND1
promoter and terminator in ERa-positive MCF7 and
T47D cells (Figure 2A). Furthermore, PRE2 also frequently
interacts with the CCND1 promoter (Figure 2B). With
DpnII 3C libraries we mapped the PRE1/CCND1 promoter
interaction to two adjacent DpnII fragments within PRE1
spanning 1.5 kb. Interestingly, this interaction was
present in the two ERa-positive cell lines, MCF7 and
T47D, but greatly reduced in ERa-negative CAL51 and
MDAMB231 cell lines (Figure 2C). Of note, SNP
rs661204 (SNP1) lies within the restriction fragment
shown to be involved in tethering the interaction.
However, allele-specific 3C on MDAMB415 cells, a cell
line heterozygous for this SNP, revealed that this SNP
had no significant effect on chromatin looping
(Figure S3). Mapping of the PRE2/CCND1 promoter inter-
action, with the same DpnII 3C libraries, showed that
PRE2 frequently interacts with the CCND1 promoter in
MCF7, T47D, and MDAMB231 cells but not in CAL51 cells
(Figure 2C), suggesting that this interaction can occur in
a cell-specific manner independent of ERa. We also de-
tected long-range chromatin interactions between PRE1
and PRE2 in MCF7 and T47D cells, suggesting that these
two regulatory elements may cooperate to regulate
CCND1 expression (Figure 2A).
Three of the Five Candidate SNPs Affect the
Regulatory Capability of PRE1 and PRE2 on
the CCND1 Promoter
By using luciferase reporter assays in MCF7 cells, we
demonstrated that PRE1 is able to act as a strong transcrip-
tional enhancer, leading to a 40-fold increase in CCND1
promoter activity (Figure 3A), whereas PRE2 ablated
CCND1 promoter activity (Figure 3C), acting as a silencer.
A similar effect was also observed in T47D and CAL51
cells (Figure S4) albeit to a lesser extent (6-fold in T47D
and 1.8-fold in CAL51 cells). To examine whether SNPs
(1–4) affect the enhancer activity of PRE1, we generated
reporter constructs containing the minor risk alleles of
these SNPs. Significantly, in MCF7 cells the minor alleles
of SNPs 2 and 3 (rs78540526 and rs554219) almost
completely abolished PRE1 enhancer activity whereas
SNPs 1 and 4 (rs661204 and rs657686) had only a minor
or no effect (Figure 3A). In T47D and CAL51 cells, similar
activities were observed (Figure S4). Consistent with ERa
ChIP-seq data (Figure S5), we find that PRE1 is estrogen
inducible. This response is not affected by the different
alleles of the four SNPs (Figure 3B). Because the silencer
strongly represses transcriptional activity, any additional
repressive effect of PRE2 SNP rs75915166 (SNP5) would
not be readily observed (Figure 3C). We therefore cloned
the PRE1 enhancer into the PRE2 constructs to increase013
Figure 2. Long-Range Chromatin Interactions of the 11q13 Risk Regions with CCND1 in Breast Cancer Cell Lines
(A and B) 3C interaction profiles between PRE1 and/or PRE2, the CCND1 promoter (P), and terminator (T) regions. 3C libraries were
generated with HindIII, with the anchor points set at either PRE1 (A) or PRE2 (B). Grey bars depict the position of the target sites and
matches them to the cartoons above each panel.
(C) Fine-mapped 3C interaction profiles between the PRE1 and fragments spanning the CCND1 promoter in ERþ (MCF7 and T47D) and
the ER (CAL51 and MDAMB231) cell lines. 3C libraries were generated with DpnII and anchor point is set at the CCND1 promoter.
(D) Fine-mapped 3C interaction profiles between the CCND1 promoter and fragments spanning PRE2. Anchor point is set at PRE2. A
representative graph of at least two biological replicates is shown.
Error bars represent SD. Physical maps of the regions interrogated by 3C are shown above (not to scale).luciferase levels (Figure 3D; PRE1þ2; PRE1þ2-S5). Impor-
tantly, we find that in the context of the PRE1 common
alleles, the minor allele of SNP5 significantly increased
the strength of the silencer (Figure 3D).
ELK4 and GATA3 Mediate the Effects of PRE1 SNP
rs554219 and PRE2 SNP rs75915166, Respectively
We used electrophoretic mobility shift assays (EMSA) to
examine protein-DNA interaction for SNPs 1–5. All five
SNPs displayed TF binding that was allele specific in four
cases (Figures 4 and S6A). Competition with known TF
binding sites suggested the identity of each of the bound
proteins (data not shown), which was confirmed in super-
shift experiments (Figure 4). Inclusion of antisera in the
binding reaction established that the common alleles of
SNPs 1 and 2 (rs661204, rs78540526) preferentially bind
USF1 and USF2. The common allele of SNP3 (rs554219)
is bound by ELK4 and GABPA, whereas the minor allele
of SNP5 (rs75915166) interacts specifically with GATA3.
A high-mobility complex bound by the oligonucleotideThe Amcontaining SNP5 is independent of allelic status and there-
fore unlikely to be relevant to cancer risk (Figure S6B). To
assess occupancy of the different SNPs in vivo, allele-
specific ChIP were carried out by TaqMan assays. Little
or no enrichment was detected for USF1 or USF2 on
SNPs 1 and 2 and no allelic discrimination was observed
(Figure S7). However, in an ELK4 ChIP assay for SNP3
(rs554219), which mediates one of the strongest effects
in the transcriptional assays, the common allele (C) shows
a 7.7-fold enrichment over a negative control and a 7.1-
fold enrichment over the risk allele, indicating that this
site is occupied in an allele-specific manner in vivo (Figures
5A and S8). GABPA, which binds the C allele of this site in
EMSAs, does not bind this site in vivo as shown by ChIP
assays (only 2.5-fold enrichment versus 160-fold enrich-
ment of a positive control; Figure S9). The importance of
ELK4 binding was confirmed in cotransfection assays
that show that two independent siRNAs against ELK4
reduce enhancer activity of wild-type enhancer, but not
of the enhancer containing the rare allele of SNP3erican Journal of Human Genetics 92, 489–503, April 4, 2013 497
Figure 3. Luciferase Reporter Assays in MCF7 Cells Demonstrating Regulatory Activity at the 11q13 Risk Locus for Breast Cancer
(A and C) PRE1 and PRE2 were cloned downstream of a CCND1 promoter-driven luciferase reporter (Pr) with and without SNPs 1–5
(rs661204, S1; rs78540526, S2; rs554219, S3; rs657686, S4; rs75915166, S5). MCF7 cells were transiently transfected with each of these
constructs and assayed for luciferase activity after 24 hr.
(B) MCF7 cells were transiently transfected with PRE1-luciferase reporter constructs, pretreated with 10 nM ICI 182780 for 24 hr, and
then stimulated with estradiol (100 nM) or vehicle for 24 hr. Luciferase activity was normalized to the activity of the vehicle-treated cells.
(D) PRE1 luciferase constructs were generated containing PRE2 with and without SNP5 (PRE1þ2; PRE1þ2-S5). MCF7 cells were tran-
siently transfected with each of these constructs and assayed for luciferase activity after 24 hr. Representative graphs are shown from
at least two independent experiments.
Error bars denote SD from one experiment performed in triplicate. p values were determined with a two-tailed t test. *p < 0.05,
***p < 0.001.(rs554219; Figure 5B), further strengthening the conclu-
sion that ELK4 is an important mediator of enhancer
function.
GATA3 in vivo binding could not be assessed because our
panel of 80 breast cancer cell lines did not include any ERþ
cell lines carrying the minor allele of rs75915166 (SNP5,
MAF ¼ 3.5%). However, with a bioinformatics approach,
we demonstrated that sequences identical to the sequence
surrounding this SNP are enriched under GATA3 ChIP-seq
signals (p < 106) and, importantly, this enrichment is498 The American Journal of Human Genetics 92, 489–503, April 4, 2higher for the risk A allele than the common C allele
(p ¼ 0.015) (Figure 5C), suggesting that our in vitro
binding results (Figure 4) are replicated in vivo. Consistent
with this, we find that the introduction of the nonbinding
C allele into the core consensus motif strongly reduces
motif enrichment. We again confirmed the functional
importance of GATA3 by using RNAi in luciferase cotrans-
fection assays: a smart pool of siRNA against GATA3
increases transcription in the presence of the minor allele,
which binds GATA3 (Figure 4) but has no effect on the013
Figure 4. Allele-Specific In Vitro Protein-DNA Interactions Detected by EMSA
Nuclear extracts from MCF7 cells were incubated with radioactively labeled oligonucleotides overlapping the SNP shown at the top of
each panel. The effect of the minor (m) and the common alleles are compared as indicated. 4 and 10 mg of antisera were included in the
reaction as listed above each lane in panels 1 and 2, and 4 mg were used in all other reactions. Bands containing antibody-protein-DNA
complexes are highlighted by open arrows.common allele (Figure 5D). Thus, we conclude that in this
context GATA3 acts as a repressor of transcription and that
the risk alleles of both PRE1 SNP rs554219 (SNP3) and
PRE2 SNP rs75915166 (SNP5) reduce transcriptional
activation.Discussion
Our fine-scale mapping of this 11q13 locus has identified
three independent association signals, each with different
effect sizes. We have been able to examine, in detail, the
ones with the strongest effects. The hits are correlated
with the originally detected GWAS tag SNP (rs614367;
r2 ¼ 0.87 with rs554219 [SNP3], r2 ¼ 0.31 with rs78540526
[SNP2], and r2 ¼ 0.57 with rs75915166 [SNP5]). These
strong candidates for being causative variants are more
strongly associatedwith breast cancer than rs614367 (Table
1). In fact, the effect sizes of these newly recognized 11q13
SNPs are now larger than the effects of the best GWAS-
discovered breast cancer locus, FGFR2 (MIM 176943; OR
overall breast cancer per minor allele ¼ 1.31; 95% CI
1.26–1.36; p value ¼ 2.93 3 1044 for 11q13 rs75915166
versus 1.27; 95% CI 1.24–1.29; p value 10129 for FGFR2
rs2981579). Thus, by fine-scale mapping, we have also
detected a little more of the ‘‘missing heritability’’ of breast
cancer. On the basis of the estimates from this iCOGs
study, the original GWAS tag SNP, rs614367, explains
approximately 0.76% of the familial risk of overall breastThe Amcancer, whereas the combined effects of SNPs rs78540526
(SNP2), rs554219 (SNP3), and rs75915156 (SNP5) explain
approximately 2.0% in Europeans.
Despite its clear value in this study, mapping by genetic
epidemiological techniques alone, even in this very large
BCAC consortium, was unable to differentiate three of
the four candidates in signal 1 (SNPs 1, 3, and 4), which
are very highly correlated in Europeans and rare in Asians,
though we were able to demonstrate an independent effect
for SNP2 (rs78540526). Of note, SNPs 3 and 4 (rs554219
and rs657686) are almost perfectly correlated (r2 ¼ 0.998)
across all participating samples in the BCAC consortium.
For signal 2, fine-scale mapping was more successful,
because no other SNPs were strongly correlated with
rs75915166 (SNP5). Our combined evidence suggests that
SNP rs75915166 is functionally related to risk. However,
it is important to bear in mind that when we selected
mapping SNPs to go onto the iCOGs chip (in March
2010), the catalog of all common variants in the locus
was not complete. Since then, reinterrogation of the
1000 Genomes data set and imputation of missing SNPs,
with the most recent (January 2012) version, has indicated
a new candidate (at chromosome 11 SNP rs12575120). It
remains possible that other candidate causal variants
may have been missed. It is worth noting, however, that
the existence of three haplotypes associated with different
risks makes it extremely unlikely (even in the absence of
functional evidence) that the associations could be driven
by rare variants missed by sequencing, because this woulderican Journal of Human Genetics 92, 489–503, April 4, 2013 499
Figure 5. Allele-Specific Effects of ELK4
and GATA3 In Vivo
(A) ChIP assays by means of polyclonal
ELK4 antiserum were carried out in
MDAMB415 cells heterozygous (G/C) for
rs554219. A TaqMan assay was used
to detect allele-specific enrichment of
rs554219, which is given relative to a nega-
tive control from the fourth intron of
CCND1. Promoter sequences from FOS
(MIM 164810) and EXOC3 (MIM 608186)
were used as positive controls.
(B) Luciferase reporter assays showing the
effect of shRNA ELK4 silencing on the
activity of PRE1 containing different
alleles of rs554219. Error bars denote SD
from two biological replicates performed
in triplicate.
(C) Allele-specific changes to in vivo
binding of GATA3. The position weight
matrix of GATA3 derived in MCF7 cells is
shown and compared to the sequence
surrounding rs75915166. Fold enrichment
of the A versus the C allele under
GATA3 ChIP-seq peaks as compared to
random genomic sequences is given for
rs75915166 and the GATA3 consensus
binding site.
(D) Luciferase reporter assays showing the
effect of GATA3 siRNA silencing on the
activity of PRE2 containing different alleles of rs75915166. Error bars denote SD from two biological replicates performed in triplicate.
p values were determined with a two-tailed t test. *p < 0.05, ***p < 0.001. Red bars indicate constructs that contain either an ELK4 or
GATA3 binding site. Levels of ELK4 and GATA3 repression are shown in Figure S10.require at least two rare variants on different haplotypes
conferring implausibly large effects.
We used functional studies to further examine the five
best candidates. We have demonstrated that SNPs 1–4 all
map to a putative CCND1 enhancer (PRE1) and that the
most plausible causal variant, SNP rs554219 (SNP3), alters
binding of the ELK4 TF both in vitro and in vivo. The
protective C allele of rs554219 preferably binds ELK4 and
absence of binding at the minor allele strongly reduces
enhancer activity in luciferase assays. This effect can be
mimicked by transfection of ELK4 siRNA. Furthermore,
presence of the risk allele correlates with reduced cyclin
D1 protein levels. Evidence for a functional role for SNP
rs78540526 (SNP2) is also strong: it is present on both
haplotypes associated with greatest breast cancer risk,
as well as significantly reducing enhancer activity in
luciferase assays and also displaying allele-specific binding
by TFs USF1 and USF2 in in vitro, but not in vivo, studies.
Finally, we demonstrate that the effects of SNP rs75915166
(SNP5) are likely to be mediated via differential binding
of TF GATA3 to this SNP position. SNP rs75915166 lies
within a silencer element able to physically interact with
the PRE1 enhancer containing SNPs 1–4. It has not yet
been possible in this study to investigate the functions of
the other potential risk variants. However, bioinformatic
analysis suggests that the T allele of SNP rs494406 may
form a GATA1 binding site and SNP rs585568 falls in
a USF ChIP-seq peak, with the minor allele forming
a MYC-MAX TF binding site. An understanding of the rele-500 The American Journal of Human Genetics 92, 489–503, April 4, 2vance of these will require even larger association studies
and then further functional analyses.
Our data implicate ELK4 and GATA3 as mediators of risk
for ERþ disease, which is consistent with previous reports
of the functions of these TFs. Expression of ELK4 is sensi-
tive to ER inhibitors23 and ChIP-seq data reveal a strong
ER binding site upstream of the ELK4 promoter. GATA3
has long been established as a critical regulator of
mammary gland development and luminal epithelial
differentiation,24,25 and loss of GATA3 is associated with
marked progression to early carcinoma.26 At the molecular
level, GATA3 influences ERa binding by modulating chro-
matin structure and long-range looping17 and, along with
FOXA1 and ERa, is a critical component of a cooperative
network of transcriptional master regulators,16,24,27 which
are sufficient to confer estrogen responsiveness to ER-nega-
tive cell lines.28 A GATA3 link with ERþ breast cancer is
further supported by the finding that tumors carrying
GATA3 mutations are all of a luminal subtype.29,30
Our findings support a hypothesis that CCND1 is the
target gene of these candidate causative SNPs—demon-
strated by the strong physical interactions between the
PREs at this locus and CCND1 and by the fact that the
risk alleles act by reducing the transcriptional activation
of CCND1. In luciferase assays, the functional risk SNPs
examined act to reduce transcriptional activity. These
conclusions may be supported by our observation of
reduced cyclin D1 protein levels in tumors homozygote
for the G allele of rs554219, but we failed to detect similar013
associations in RNA expression data. Our power to detect
any such association was limited—we estimate that the
300 TCGA tumors analyzed provided 70% power to detect
a 10% difference in expression associated with this risk
allele (MAF ¼ 0.12). However, it is also possible that any
effect of this SNP on expression levels is not apparent in
breast tumor cells. There is precedent for this in that the
confirmed multicancer risk SNPs at 8q24 (upstream of
MYC)31 have consistently failed to show any associations
with gene expression in human cell types but have been
confirmed as functionally important in this respect when
analyzed in transgenic mouse models.32
Cyclin D1 is traditionally considered to be an oncogene,
based on its overexpression in tumors, its well-established
role in cell cycle control, and its ability to promote cell
migration and differentiation.33,34 Consequently, germ-
line variants that repress this gene are somewhat at odds
with the accepted dogma of cancer-susceptibility genes.
Resolution of this apparent conflict may, however, come
from the complexity of cyclin D1 function, the heteroge-
neity of cyclin D1 protein levels in human tumors, and
the fact that the moderate risk we describe is likely to
work in concert with a number of other coinherited vari-
ants that may facilitate some lesser known activities of
this protein.
In terms of function, repression of cyclin D1 has been re-
ported to induce cell migration of breast cancer cell lines
and be associated with the epithelial-mesenchymal transi-
tion (EMT).35 Cyclin D1 also interacts with a range of TFs,
including steroid hormone receptors36,37 and chromatin-
modifying enzymes,37,38 and is able to participate in
a broad range of other functions. A recent study provides
evidence that cyclin D1 promotes homologous recombina-
tion-mediated DNA repair (HRR) by recruiting RAD51 to
double-strand breaks, a role that is independent of its
control of the cell cycle.39 Notably, depletion of CCND1
levels impairs HRR and increases sensitivity of cells to
DNA-damaging agents such as ionizing radiation in vitro
and in vivo.39 It is thus conceivable that, in a similar way
to BRCA1 and BRCA2 that also function in HRR, reduced
cyclin D1 levels may lead to more error-prone repair mech-
anisms, potentially promoting genome instability and
cancer predisposition.
Many of these roles are in fact more in-line with a tumor
suppressor, suggesting that cyclin D1 can operate both as
an oncogene and a tumor suppressor depending on the
context, with the latter being particularly relevant in the
case of germline events resulting in loss of cyclin D1. There
are certainly precedents for this: RET (MIM 164761), for
example, acts as an oncogene in the thyroid gland and
a tumor-suppressor gene in the colon.40 Consistent with
this, Lehn and colleagues have reported an association
between downregulation of cyclin D1 and unfavorable
prognosis in human breast cancer.41 We therefore propose
that germline events leading to a reduction of cyclin D1,
such as described in the manuscript, contribute to breast
tumorigenesis.The AmAlthough our data indicate that CCND1 is the target
gene, we cannot rule out the possibility that these SNPs
also exert functional effects through long-range control
of other nearby genes: MYEOV, ORAOV1, or FGF3, FGF4,
or FGF19, all of which are plausible candidates for breast
cancer susceptibility. MYEOV is very frequently coampli-
fied with CCND1 in ERþ breast cancer42 and cyclin D1
protein levels are reduced in HeLa cells in which ORAOV1
proto-oncogene levels have been knocked down to induce
apoptosis;43 FGF3, FGF4, and FGF19 belong to the Fibro-
blast Growth Factor family, which plays a key role in tumor
pathogenesis via their receptors—including FGFR2, the
strongest common breast cancer susceptibility locus re-
ported to date.44–46
This 11q13 genomic interval also contains GWAS hits
for renal cancer and functional studies there indicate that
a candidate causal variant affects the activity of an
enhancer element probably also driving CCND1 transcrip-
tion.47 This region may thus share similarities with the
8q24 interval, where a large ‘‘gene desert’’ contains
multiple tissue-specific enhancers in which risk-associated
SNPs affect the transcription of downstream oncogene(s)
and predispose to cancer in a tissue-specific manner.47
The variants described here predispose only to ERþ disease
and we find that the identified molecular mechanisms
underlying this risk are fully consistent with this observa-
tion: long-range physical interactions between the
enhancer and the CCND1 promoter are found only in
ERþ cells and GATA3, which binds PRE1 SNP3
(rs554219), is coregulated with the ER and is part of the
network of transcriptional master regulators able to estab-
lish estrogen responsiveness.28,29,48
In conclusion we have identified three SNPs as being
very strong candidates for having a directly causative
effect on breast cancer risk at this locus and we have
provided evidence that these act by controlling CCND1
expression—a gene that is a potential target for drug
intervention.Supplemental Data
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